MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer

Human Pathology

Volumn 44, Issue 10, 2013, Pages 2159-2166

  Siroy, Alan ^a   Abdul Karim, Fadi W ^b   Miedler, John ^a   Fong, Nancy ^c   Fu, Pingfu ^d   Gilmore, Hannah ^a   Baar, Joseph ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c FAIRVIEW HOSPITAL   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Basal like; Mucin; Triple negative breast cancer

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; MUCIN 1;

ADULT; AGED; APICAL MEMBRANE; ARTICLE; BASAL LIKE BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL; TUMOR IMMUNITY; TUMOR VOLUME;

BASAL-LIKE; MUCIN; TRIPLE-NEGATIVE BREAST CANCER;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; EARLY DIAGNOSIS; FEMALE; HUMANS; MIDDLE AGED; MUCIN-1; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84884413941     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2013.04.010     Document Type: Article

References (27)

1. American Cancer Society What are the key statistics about breast cancer? http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-key- statistics 2013
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) R. Peto, and C. Davies Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials Lancet 379 2012 432 444
3. C.M. Perou, T. Sorlie, and M.B. Eisen Molecular portraits of human breast tumours Nature 406 2000 747 752
4. T. Sorlie, C.M. Perou, and R. Tibshirani Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci U S A 98 2001 10869 10874
5. E.A. Rakha, M.E. El-Sayed, and A.R. Green Prognostic markers in triple-negative breast cancer Cancer 109 2007 25 32
6. B.G. Haffty, Q. Yang, and M. Reiss Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer J Clin Oncol 24 2006 5652 5657
7. F. Bertucci, P. Finetti, and N. Cervera How basal are triple-negative breast cancers? Int J Cancer 123 2008 236 240
8. T. Sorlie, R. Tibshirani, and J. Parker Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci U S A 100 2003 8418 8423
9. G. Von Minckwitz, W. Jonat, and P. Fasching A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer Breast Cancer Res Treat 89 2005 165 172
10. M.D. Green, P.A. Francis, and V. Gebski Gefitinib treatment in hormone-resistant and hormone receptor negative advanced breast cancer Ann Oncol 20 2009 1813 1817
11. J. O'Shaughnessy, C. Osborne, and J.E. Pippen Iniparib plus chemotherapy in metastatic triple-negative breast cancer N Engl J Med 364 2011 205 214
12. O.J. Finn, K.R. Jerome, and R.A. Henderson MUC1 epithelial tumor mucin-based immunity and cancer vaccines Immunol Rev 145 1995 61 89
13. R.A. Graham, J.M. Burchell, and J. Taylor-Papadimitriou The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine Cancer Immunol Immunother 42 1996 71 80
14. S. Gendler, J. Taylor-Papadimitriou, T. Duhig, J. Rothbard, and J. Burchell A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats J Biol Chem 263 1988 12820 12823
15. E.M. Hiltbold, P. Ciborowski, and O.J. Finn Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells Cancer Res 58 1998 5066 5070
16. E.M. Hiltbold, M.D. Alter, P. Ciborowski, and O.J. Finn Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken up by dendritic cells Cell Immunol 194 1999 143 149
17. V. Karanikas, L.A. Hwang, and J. Pearson Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein J Clin Invest 100 1997 2783 2792
18. R.K. Ramanathan, K.M. Lee, and J. McKolanis Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer Cancer Immunol Immunother 54 2005 254 264
19. V. Apostolopoulos, G.A. Pietersz, and A. Tsibanis Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835] Breast Cancer Res 8 R27 2006 1304
20. J.J. Rahn, L. Dabbagh, M. Pasdar, and J.C. Hugh The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature Cancer 91 2001 1973 1982
21. E.A. Rakha, R.W. Boyce, and Abd El-Rehim Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer Mod Pathol 18 2005 1295 1304
22. P. Ciborowski, and O.J. Finn Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis Clin Exp Metastasis 19 2002 339 345
23. B. van der Vegt, M.A. de Roos, and J.L. Peterse The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma J Histopathol 51 2007 322 335
24. G. Viale, N. Rotmensz, and P. Maisonneuve Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity Breast Cancer Res Treat 116 2009 317 328
25. J. Foley, N.K. Nickerson, S. Nam, K.T. Allen, J.T. Gilmore, K.P. Nephew, and D.J. Riese 2nd EGFR signaling in breast cancer: bad to the bone Semin Cell Dev Biol 21 2010 951 960
26. B.G. Bitler, A. Goverdhan, and J.A. Schroeder MUC1 regulates nuclear localization and function of the epidermal growth factor receptor J Cell Sci 123 2010 1716 1723
27. M.R. Pochampalli, R.M. el Bejjani, and J.A. Schroeder MUC1 is a novel regulator of ErbB1 receptor trafficking Oncogene 26 2007 1693 1701